Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma

RECIST v1.1 has limitations in evaluating progression. We assessed Dynamic Constrast Enhanced Computed Tomography (DCE-CT) identified Blood Volume (BV) for the evaluation of progressive disease (PD) in patients with metastatic renal cell carcinoma (mRCC). BV was quantified prospectively at baseline,...

Descripción completa

Detalles Bibliográficos
Autores principales: Drljevic-Nielsen, Aska, Rasmussen, Finn, Mains, Jill Rachel, Thorup, Kennet, Donskov, Frede
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490379/
https://www.ncbi.nlm.nih.gov/pubmed/34608226
http://dx.doi.org/10.1038/s41598-021-99122-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490379/
https://www.ncbi.nlm.nih.gov/pubmed/34608226
http://dx.doi.org/10.1038/s41598-021-99122-1

Ejemplares similares